Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Laura Path Recall > Immunomodulatory Therapies > Flashcards

Immunomodulatory Therapies Flashcards

1
Q

MOA: Corticosteroids

A

Inhibit phospholipase A2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Inhibit phospholipase A2

A

MOA: Corticosteroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

MOA: Tacrolimus

A

Calcinurin Inhibitor, block cytokine transcription

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MOA: Cyclosporin

A

Calcinurin Inhibitor, block cytokine transcription

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Calcinurin Inhibitor, block cytokine transcription (x2)

A

Tacrolimus, cyclosporin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

MOA: Tofacitinib

A

JAK inhibitor, inhibits cell signalling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

JAK inhibitor, inhibits cell signalling

A

Tofacitinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

MOA: Sirolimus

A

blocks clonal T cell proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

MOA: Apremilast

A

PDE4 inhibitor, inhibits cell signalling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

PDE4 inhibitor, inhibits cell signalling

A

Apremilast

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MOA: Basiliximab

A

ab vs. CD25, anti-IL2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ab against CD25 on IL-2 receptor (x2)

A

Basiliximab, Daclizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Indication: Basiliximab, Daclizumab

A

Rejection prophylaxis in transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Indication: Tacrolimus

A

Rejection prophylaxis in transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Indication: Cyclosporin

A

Rejection prophylaxis in transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Indication: Sirolimus

A

Rejection prophylaxis in transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Indication: Tofacitinib

A

Rheumatoid arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Indication: Apremilast

A

Psoriasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Indication: Abatacept

A

Rheumatoid arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

MOA: Abatacept

A

CTLA4-Ig fusion protein, (directed against cell surface antigens to ↓T cell activation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

CTLA4-Ig fusion protein, (directed against cell surface antigens to ↓T cell activation)

A

Abatacept

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

MOA: Rituximab

A

ab vs. CD20, depletes mature B cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

ab vs. CD20, depletes mature B cells

A

Rituximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Indications: Rituximab

A

RhA, SLE, lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
MOA: Toclizumab
ab vs. IL-6 receptor, ↓activation of neuts, B/T cells, macrophages
26
ab vs. IL-6 receptor, ↓activation of neuts, B/T cells, macrophages
Toclizumab
27
Indications: Toclizumab
Castleman's disease, Rheumatoid arthritis
28
MOA: Natalizumab
ab vs. a4 integrin, ↓T cell migration
29
ab vs. a4 integrin, ↓T cell migration
Natalizumab
30
Indications: Natalizumab
active MS
31
MOA: Daclizumab
ab against CD25 on IL-2 receptor
32
MOA: Alemtuzumab
ab vs. CD52, ↓lymphocytes
33
ab vs. CD52, ↓lymphocytes
Alemtuzumab
34
Indications: Alemtuzumab
MS, CLL
35
MOA: Muromonab-CD3
Blocks CD3 on T cell
36
Blocks CD3 on T cell
Muromonab-CD3
37
Indications: Muromonab-CD3
Active transplant rejection
38
MOA: Efalizumab
anti CD-IIa, ↓T cell migration
39
anti CD-IIa, ↓T cell migration
Efalizumab
40
Indications: Efalizumab
AI disease
41
MOA: Anti-thymocyte globulin
(rabbit), modulates T cell activation and migration, ↓lymphocytes
42
(rabbit), modulates T cell activation and migration, ↓lymphocytes
Anti-thymocyte globulin
43
Indications: Anti-thymocyte globulin
Acute transplant rejection
44
MOA: Methotrexate
Inhibits DHFR, anti-proliferative agent
45
Inhibits DHFR, anti-proliferative agent
Methotrexate
46
Indications: Methotrexate
RhA, psoriasis, Crohn's, chemo, abortifacient
47
MOA: Cyclophosphamide
alkylates guanine bases of DNA B>T cells Anti-proliferative agent
48
alkylates guanine bases of DNA B>T cells Anti-proliferative agent
Cyclophosphamide
49
Indications: Cyclophosphamide
Connetive tissue disease, vasculitis with end organ damage
50
MOA: Azathioprine
Blocks purine synthesis T cells Anti-metabolic, (converted to 6-mercaptopurine) Anti-proliferative agent
51
Blocks purine synthesis T cells Anti-metabolic, (converted to 6-mercaptopurine) Anti-proliferative agent
Azathioprine
52
Indications: Azathioprine
Transplant, AI disease, auto-inflammatory diseases (eg. Crohn's disease, UC)
53
MOA: Mycophenolate Mofetil
Inhibits IM PDH, blocks nucleotide synthesis T>B cells Anti-proliferative agent
54
Inhibits IM PDH, blocks nucleotide synthesis T>B cells Anti-proliferative agent
Mycophenolate Mofetil
55
Indications: Mycophenolate Mofetil
2nd line for transplant, AI disease, vasculitis
56
MOA: Infliximab
anti-TNFa
57
MOA: Adalimumab
anti-TNFa
58
MOA: Certolizumab
anti-TNFa
59
MOA: Golimumab
anti-TNFa
60
anti-TNFa (x4)
Infliximab, Adalimumab, Certolizumab, Golimumab
61
Indications: Infliximab, Adalimumab, Certolizumab, Golimumab (anti-TNFa)
Psoriasis, psoriatic arthritis, IBD, RhA, ank spond
62
MOA: Etanercept
Inhibits TNFa and TNFB
63
Inhibits TNFa and TNFB
Etanercept
64
Indications: Etanercept
Psoriasis, psoriatic arthritis, IBD, RhA, ank spond
65
MOA: Ustekinumab
ab inhibits IL-12 and IL-23
66
ab inhibits IL-12 and IL-23
Ustekinumab
67
Indications: Ustekinumab
Psoriasis, psoriatic arthritis, Crohn's
68
MOA: Secukinumab
ab vs. IL17A
69
ab vs. IL17A
Secukinumab
70
Indications: Secukinumab
Ank spond, psoriasis, psoriatic arthritis,
71
MOA: Denosumab
ab vs. RANK ligand, ↓osteoclasts
72
ab vs. RANK ligand, ↓osteoclasts
Denosumab
73
Indications: Denusumab
Osteoporosis
74
MOA: Ipilimumab
mab vs CTLA4 | *Boosts immune system by blocking checkpoints, ↑T cell activation*
75
mab vs CTLA4 | *Boosts immune system by blocking checkpoints*
Ipilimumab
76
Indications: Ipilimumab
Advanced melanoma
77
MOA: Pemibrolizumab/Nivolumab
ab vs. PD-1 | *Boosts immune system by blocking checkpoints, ↑T cell activation*
78
ab vs. PD-1 | *Boosts immune system by blocking checkpoints, ↑T cell activation*
Pemibrolizumab/Nivolumab
79
Indications: Pemibrolizumab/Nivolumab
Advanced melanoma

Laura Path Recall (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions